Evidence-Based Nursing of a Patient with Grade III Hand-foot Syndrome Induced by Capecitabine_Chinese Journal of Evidence-Based Medicine

Authors：

Chen Huaying ,  LI JIping

1. Department of Oncology Ward 1,West China Hospital, Sichuan University, Chengdu 610041, China;2. Department of Nursing, West China Hospital, Sichuan University, Chengdu 610041, China.;

Corresponding author：

LI JIping, Email: JP-Li@163.com

Keywords：

Capecitabine; Hand-toot syndrome; Evidence-based nursing

DOI：

10.7507/1672-2531.20080197

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To formulate an evidence-based nursing methods for a patient with grade III handfoot syndrome induced by capecitabine.
Methods 　Based on the cl inical questions, we searched The Cochrane Library (Issue 1, 2008), ACP Journal Club (1991 to January 2008), MEDLINE (1996 to 2008) and CBMdisc (1995 to 2008). The retrieved studies were further critically appraised.
Results 　There were two effective measures in patients with grade III hand-foot syndrome induced by capecitabine: ① Treatment interruption or dose reduction with supportive measures to reduce pain and discomfort and prevent secondary infection. ② Using Traditional Chinese Medicine and no need of treatment interruption or dose reduction. With patients preference, Treatment interruption and supportive measures were administered to the patient. After two weeks, the patient had a complete response.
Conclusions 　 To patients with grade III hand-foot syndrome induced by capecitabine, treatment interruption and supportive measures are effective nursing methods.

Citation： Chen Huaying,LI JIping. Evidence-Based Nursing of a Patient with Grade III Hand-foot Syndrome Induced by Capecitabine. Chinese Journal of Evidence-Based Medicine, 2008, 08(10): 898-900. doi: 10.7507/1672-2531.20080197 Copy

1.	Courneya KS, Friedenreich CM. Physical exercise and qual ity of life following cancer diagnosis: a literature review. Annals of Behavioural Medicine, 1999, 21: 171-179.
2.	Wilmoth MC, Coleman EA, Smith SC, et al. Fatigue, weight gain, and altered sexuality in patients with breast cancer: exploration of a symptom cluster. Oncol Nurs Forum, 2004, 31: 1069-1075.
3.	Irwin M, Crumley D, McTiernan A, et al. Physical activity levels before and after a diagnosis of breast carcinoma. Cancer, 2003, 97: 1746-1757.
4.	Irwin M, McTiernan A, Bernstein L, et al. Physical activity levels among breast cancer survivors. Med Sci Sports Exerc, 2004, 36: 1484-1491.
5.	Scheithauer W, McKendrick J, Begbie S, et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol, 2003, 14(12): 1735-1743.
6.	王玲, 焦智民, 李平. 中药内服外洗治疗希罗达所致中重度手足综合征8例. 中医研究, 2006, 19(4): 40-42.
7.	王涛, 江泽飞, 宋三泰, 等. 希罗达治疗乳腺癌所致手足综合征的发生规律及临床处理.癌症进展杂志, 2004, 2(4): 258-260.
8.	Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs, 2004, 8(Suppl 1): S31-40.
9.	王琰, 徐瑞荣. 希罗达所致手足综合征中、西医防治措施研究进展. 中国中西医结合杂志, 2007, 27(2): 182-184.
10.	Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract, 2006, 12(3): 131-141.
11.	Marsé H, Van Cutsem E, Grothey A, et al. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs, 2004, 8(Suppl 1): S16-30.
12.	Lee SD, Kim HJ, Hwang SJ, et al. Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: a case report. Korean J Intern Med, 2007, 22(2): 109-112.
13.	Narasimhan P, Narasimhan S, Hitti IF, et al. Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature. Cutis, 2004, 73(2): 101.
14.	肖凤霞. 口服希罗达所致手足综合征的护理. 现代护理, 2006, 12(21): 21-22.
15.	王磊. 希罗达(卡培他滨)致严重手足综合征1例. 中国药物应用与监测, 2007, 3: 98.
16.	杨圣菊, 陈晓栋, 王建力. 卡培他滨引起Ⅲ度手足综合征1例. 临床皮肤科杂志, 2007, 36(4): 250.
17.	Yucel I, Guzin G. Topical henna for capecitabine induced hand-foot syndrome.Invest New Drugs. 2007 Sep 21 [Epub ahead of print].
18.	Kern E, Schmidinger M, Locker GJ, et al. Management of capecitabine-induced hand-foot syndrome by local phytotherapy. Wien Med Wochenschr, 2007, 157(13-14): 337-42.

1. Courneya KS, Friedenreich CM. Physical exercise and qual ity of life following cancer diagnosis: a literature review. Annals of Behavioural Medicine, 1999, 21: 171-179.
2. Wilmoth MC, Coleman EA, Smith SC, et al. Fatigue, weight gain, and altered sexuality in patients with breast cancer: exploration of a symptom cluster. Oncol Nurs Forum, 2004, 31: 1069-1075.
3. Irwin M, Crumley D, McTiernan A, et al. Physical activity levels before and after a diagnosis of breast carcinoma. Cancer, 2003, 97: 1746-1757.
4. Irwin M, McTiernan A, Bernstein L, et al. Physical activity levels among breast cancer survivors. Med Sci Sports Exerc, 2004, 36: 1484-1491.
5. Scheithauer W, McKendrick J, Begbie S, et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol, 2003, 14(12): 1735-1743.
6. 王玲, 焦智民, 李平. 中药内服外洗治疗希罗达所致中重度手足综合征8例. 中医研究, 2006, 19(4): 40-42.
7. 王涛, 江泽飞, 宋三泰, 等. 希罗达治疗乳腺癌所致手足综合征的发生规律及临床处理.癌症进展杂志, 2004, 2(4): 258-260.
8. Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs, 2004, 8(Suppl 1): S31-40.
9. 王琰, 徐瑞荣. 希罗达所致手足综合征中、西医防治措施研究进展. 中国中西医结合杂志, 2007, 27(2): 182-184.
10. Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract, 2006, 12(3): 131-141.
11. Marsé H, Van Cutsem E, Grothey A, et al. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs, 2004, 8(Suppl 1): S16-30.
12. Lee SD, Kim HJ, Hwang SJ, et al. Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: a case report. Korean J Intern Med, 2007, 22(2): 109-112.
13. Narasimhan P, Narasimhan S, Hitti IF, et al. Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature. Cutis, 2004, 73(2): 101.
14. 肖凤霞. 口服希罗达所致手足综合征的护理. 现代护理, 2006, 12(21): 21-22.
15. 王磊. 希罗达(卡培他滨)致严重手足综合征1例. 中国药物应用与监测, 2007, 3: 98.
16. 杨圣菊, 陈晓栋, 王建力. 卡培他滨引起Ⅲ度手足综合征1例. 临床皮肤科杂志, 2007, 36(4): 250.
17. Yucel I, Guzin G. Topical henna for capecitabine induced hand-foot syndrome.Invest New Drugs. 2007 Sep 21 [Epub ahead of print].
18. Kern E, Schmidinger M, Locker GJ, et al. Management of capecitabine-induced hand-foot syndrome by local phytotherapy. Wien Med Wochenschr, 2007, 157(13-14): 337-42.

Previous Article
Effectiveness and Safety of Fuzheng Huayu Capsule for Liver Fibrosis of Chronic Hepatitis B: A Systematic Review
Next Article
Regulations of VEP Changes in 30 Patients with Multiple Sclerosis

Chinese Journal of Evidence-Based Medicine

Evidence-Based Nursing of a Patient with Grade III Hand-foot Syndrome Induced by Capecitabine

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content